Phase 2a study of LX2931 for the treatment of rheumatoid arthritis (RA)
Lexicon Pharmaceuticals announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA). Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all 3 doses tested, 70mg, 110mg, and 150mg given once per day, were well tolerated over the 12-week treatment period. Taken together, the data also suggested that patients treated with 150mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo). Patients treated with 70mg or 110mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo.
LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues.
For more information call (281) 863-3000 or visit www.lexpharma.com.